Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Cancer remains a leading cause of death globally, with many patients unresponsive to current therapies.
• T-cell-mediated anti-tumor responses are crucial for cancer control, making T-lymphocytes a focus for cancer immunotherapy.
• Adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) has a long history in treating metastatic melanoma.

Purpose of the Study:

• To review the history and current clinical development of ACT-TIL in solid tumors.
• To discuss advancements improving TIL therapy efficacy, including neoantigen identification and overcoming immune suppression.
• To explore strategies for enhancing TIL product characteristics and in vivo functionality.

Main Methods:

• Review of historical data and current clinical trial outcomes for ACT-TIL.
• Analysis of recent research on genetic intratumor heterogeneity and neoantigen discovery.
• Examination of novel strategies to combat T-cell exhaustion and tumor immunosuppression.

Main Results:

• ACT-TIL has shown potential as a personalized approach, particularly for epithelial tumors.
• Key advances in understanding tumor biology and T-cell immunology are improving TIL therapy effectiveness.
• Ongoing research is expanding the application of TIL therapy to a broader range of cancers.

Conclusions:

• ACT-TIL represents a significant advancement in personalized cancer immunotherapy.
• Continued research and technological innovation are poised to further enhance the efficacy and applicability of TIL therapy.
• The field is moving towards more effective and broadly applicable cellular therapies for various cancer types.